Previous 10 | Next 10 |
BofA Securities screened for stocks with the the characteristics most likely to attract suitors, both in the large- and small-cap universes. For S&P 500 (SP500) (SPY) targets, BofA: Screens based on its preferred valuation metric of free cash flow to enterprise value (FCF/EV) for those tr...
Vanda Pharmaceuticals Inc. (VNDA) Q1 2022 Earnings Conference Call May 5, 2022, 4:30 PM ET Company Participants Mihael H. Polymeropoulos – President & Chief Executive Officer Kevin Moran – Senior Vice President & Chief Financial Officer Conference Call Participants Prese...
Vanda Pharmaceuticals press release (NASDAQ:VNDA): Q1 GAAP EPS of -$0.11 misses by $0.10. Revenue of $60.19M (-4.0% Y/Y) beats by $2.19M. For further details see: Vanda Pharmaceuticals GAAP EPS of -$0.11 misses by $0.10, revenue of $60.19M beats by $2.19M
Vanda Pharmaceuticals Reports First Quarter 2022 Financial Results PR Newswire WASHINGTON , May 5, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the first quarter ended March 31,...
Vanda Pharmaceuticals Announces Participation in the BofA Securities 2022 Healthcare Conference PR Newswire WASHINGTON , May 4, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the BofA Se...
Vanda Pharmaceuticals to Announce First Quarter 2022 Financial Results on May 5, 2022 PR Newswire Conference Call and Webcast to Follow WASHINGTON , April 28, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will r...
Amid the biotech bear market, many fundamentally sound companies are trading at a fraction of their intrinsic value. The best situation is when you have a growth stock that is trading near its cash position. Enjoying increasing sales and a positive cash flow, Vanda Pharmaceuticals...
Vanda Pharmaceuticals Inc. (VNDA) Q4 2021 Earnings Conference Call February 23, 2022 16:30 ET Company Participants Kevin Moran - Senior Vice President & Chief Financial Officer Mihael Polymeropoulos - President & Chief Executive Officer Gunther Birznieks - Senior Vice President of Bus...
Vanda Pharmaceuticals press release (NASDAQ:VNDA): Q4 GAAP EPS of $0.12. Revenue of $68.01M (+0.5% Y/Y). For further details see: Vanda Pharmaceuticals GAAP EPS of $0.12, revenue of $68.01M
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results - Full year 2021 total revenues grew to $268.7 million, an 8% increase compared to 2020 - Full year 2022 total revenues expected to be between $240 million and $280 million - End of year 20...
News, Short Squeeze, Breakout and More Instantly...
Vanda Pharmaceuticals Inc. Company Name:
VNDA Stock Symbol:
NASDAQ Market:
Vanda Pharmaceuticals Inc. Website:
2024-07-17 04:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-11 07:00:07 ET Charles Duncan from Cantor Fitzgerald issued a price target of $11.00 for VNDA on 2024-07-11 06:12:00. The adjusted price target was set to $11.00. At the time of the announcement, VNDA was trading at $5.21. VNDA currently trades -22.96% versus its...
Federal Court Allows Vanda's HETLIOZ® Patent Lawsuit to Proceed against Teva and Apotex PR Newswire WASHINGTON , July 1, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. District Court for the District of ...